Table 2 Clinical trials for MSLN-targeted therapies based on CAR-T therapy
NCT Number | Title | Status | Interventions | Phases | Enrollment | Start Date | Locations |
|---|---|---|---|---|---|---|---|
NCT03814447 | The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer | Not yet recruiting | Drug: anti- MESO CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide | Early Phase 1 | 10 | 2019-04-01 | China |
NCT03747965 | Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors | Recruiting | Biological: Mesothelin-directed CAR-T cells | Phase 1 | 10 | 2018-11-01 | China |
NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | Recruiting | Biological: MCY-M11 | Phase 1 | 15 | 2018-08-27 | United States |
NCT03615313 | PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor | Recruiting | Biological: PD-1 antibody expressing mesoCAR-T cells | Phase 1/2 | 50 | 2018-08-06 | China |
NCT03638193 | Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | Recruiting | Biological: CART-meso cells | Not Applicable | 10 | 2018-07-11 | China |
NCT03545815 | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. | Recruiting | Biological: anti-mesothelin CAR-T cells | Phase 1 | 10 | 2018-03-01 | China |
NCT03356808 | Antigen-specific T Cells Against Lung Cancer | Recruiting | Biological: Lung cancer-specific T cells | Phase 1/2 | 20 | 2017-12-15 | China |
NCT03356795 | Intervention of CAR-T Against Cervical Cancer | Recruiting | Biological: Cervical cancer-specific CAR-T cells | Phase 1/2 | 20 | 2017-11-15 | China |
NCT03497819 | Autologous CARTmeso/19 Against Pancreatic Cancer | Active, not recruiting | Biological: CARTmeso CART19 | Early Phase 1 | 10 | 2017-10-01 | China |
NCT03323944 | CAR T Cell Immunotherapy for Pancreatic Cancer | Recruiting | Biological: huCART-meso cells | Phase 1 | 18 | 2017-09-15 | United States |
NCT03198052 | HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers | Recruiting | Biological: CAR-T cells targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, or CD80/86 | Phase 1 | 30 | 2017-07-01 | China |
NCT03267173 | Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | Recruiting | Drug: Chimeric antigen receptor T cell | Early Phase 1 | 10 | 2017-06-15 | China |
NCT03182803 | CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor | Recruiting | Biological: CTLA-4/PD-1 antibodies expressing mesoCAR-T | Phase 1/2 | 40 | 2017-06-07 | China |
NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | Recruiting | Biological: huCART-meso cells | Phase 1 | 30 | 2017-03-01 | United States |
NCT03030001 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | Unknown status | Biological: PD-1 antibody expressing mesothelin specific CAR-T cells | Phase 1/2 | 40 | 2017-02-15 | China |
NCT02930993 | Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors | Recruiting | Biological: anti-mesothelin CAR T cells | Phase 1 | 20 | 2016-08-01 | China |
NCT02959151 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | Unknown status | Drug: CAR-T cell | Phase 1/2 | 20 | 2016-07-01 | China |
NCT02792114 | T-Cell Therapy for Advanced Breast Cancer | Recruiting | Drug: Cyclophosphamide; Biological: Mesothelin-targeted T cells; Drug: AP1903 | Phase 1 | 36 | 2016-06-01 | United States |
NCT02706782 | A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma | Unknown status | Drug: TAI-meso-CART | Phase 1 | 30 | 2016-03-01 | China |
NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | Unknown status | Biological: anti-meso-CAR vector transduced T cells | Phase 1 | 20 | 2015-10-01 | China |
NCT02414269 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Recruiting | Genetic: iCasp9M28z T cell infusions; Drug: cyclophosphamide | Phase 1 | 48 | 2015-05-01 | United States |
NCT02465983 | Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | Completed | Biological: CART-meso-19 T cells; Drug: Cyclophosphamide | Phase 1 | 4 | 2015-05-01 | United States |
NCT02388828 | CART-meso Long-term Follow-up | Active, not recruiting | Biological: lentiviral-based CART meso therapy | 10 | 2015-03-01 | United States | |
NCT02159716 | CART-meso in Mesothelin Expressing Cancers | Completed | Biological: CART-meso | Phase 1 | 19 | 2014-06-01 | United States |
NCT01897415 | Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer | Completed | Biological: Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 | Phase 1 | 16 | 2013-07-01 | United States |
NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | Terminated | Drug: Fludarabine; Biological: Anti-mesothelin CAR transduced PBL; Drug: Cycolphosphamide; Drug: Aldesleukin | Phase 1/2 | 15 | 2012-05-04 | United States |
NCT01355965 | Autologous Redirected RNA Meso-CIR T Cells | Completed | Biological: Autologous T cells | Phase 1 | 18 | 2011-03-01 | United States |